In this episode, Dr. Valentin Fuster dives into the complex and high-stakes world of cardiogenic shock, spotlighting new clinical trials, expert consensus guidance, and cutting-edge insights from machine learning. From evaluating the impact of intra-aortic balloon pumps to rethinking mechanical support strategies, the episode delivers a powerful update on one of cardiology's most urgent challenges.
In this episode, Dr. Valentin Fuster dives into the complex and high-stakes world of cardiogenic shock, spotlighting new clinical trials, expert consensus guidance, and cutting-edge insights from machine learning. From evaluating the impact of intra-aortic balloon pumps to rethinking mechanical support strategies, the episode delivers a powerful update on one of cardiology's most urgent challenges.
In this episode, Dr. Valentin Fuster dives into the complex and high-stakes world of cardiogenic shock, spotlighting new clinical trials, expert consensus guidance, and cutting-edge insights from machine learning. From evaluating the impact of intra-aortic balloon pumps to rethinking mechanical support strategies, the episode delivers a powerful update on one of cardiology's most urgent challenges.
In this episode, Dr. Valentin Fuster dives into the complex and high-stakes world of cardiogenic shock, spotlighting new clinical trials, expert consensus guidance, and cutting-edge insights from machine learning. From evaluating the impact of intra-aortic balloon pumps to rethinking mechanical support strategies, the episode delivers a powerful update on one of cardiology's most urgent challenges.
In this episode, Dr. Valentin Fuster dives into the complex and high-stakes world of cardiogenic shock, spotlighting new clinical trials, expert consensus guidance, and cutting-edge insights from machine learning. From evaluating the impact of intra-aortic balloon pumps to rethinking mechanical support strategies, the episode delivers a powerful update on one of cardiology's most urgent challenges.
In this episode, Dr. Valentin Fuster dives into the complex and high-stakes world of cardiogenic shock, spotlighting new clinical trials, expert consensus guidance, and cutting-edge insights from machine learning. From evaluating the impact of intra-aortic balloon pumps to rethinking mechanical support strategies, the episode delivers a powerful update on one of cardiology's most urgent challenges.
In this episode, Dr. Valentin Fuster dives into the complex and high-stakes world of cardiogenic shock, spotlighting new clinical trials, expert consensus guidance, and cutting-edge insights from machine learning. From evaluating the impact of intra-aortic balloon pumps to rethinking mechanical support strategies, the episode delivers a powerful update on one of cardiology's most urgent challenges.
In this episode, Dr. Valentin Fuster dives into the complex and high-stakes world of cardiogenic shock, spotlighting new clinical trials, expert consensus guidance, and cutting-edge insights from machine learning. From evaluating the impact of intra-aortic balloon pumps to rethinking mechanical support strategies, the episode delivers a powerful update on one of cardiology's most urgent challenges.
In this episode, Dr. Valentin Fuster dives into the complex and high-stakes world of cardiogenic shock, spotlighting new clinical trials, expert consensus guidance, and cutting-edge insights from machine learning. From evaluating the impact of intra-aortic balloon pumps to rethinking mechanical support strategies, the episode delivers a powerful update on one of cardiology's most urgent challenges.
Listen to the editor's page for this special issue of JACC focusing on advancing the understanding and treatment of cardiogenic shock through pivotal clinical trials, expert consensus statements, and state-of-the-art reviews aimed at improving patient outcomes. Join Editor-in-Chief Harlan Krumholz as he highlighs key contributions like the Altshock-2 trial and new ACC guidelines, the issue underscores the journal's commitment to leading cardiovascular care in this complex field.
Hosts Mitsuaki Sawano, MD, and Nobuhiro Ikemura, MD, welcome Yuichiro Mori, MD, MPH, a physician-scientist at Kyoto University, to discuss his ACC.25 poster presentation on biomarker-based pre-heart failure screening using NT-proBNP, conducted in a rural Japanese city in Hokkaido. Drawing from a screening cohort of 1,585 individuals aged 40–74 in Furano, the study integrated NT-proBNP testing into Japan's routine general health checkups. Dr. Mori shares key takeaways from the study and emphasize...
Listen to the editor's page of the April 14th JACC issue for a discussion about the staggering toll of cardiovascular disease on Black Americans, revealing nearly 800,000 excess deaths and 23.7 million years of potential life lost over two decades. Join Editor-in-Chief Harlan Krumholz as he explores the systemic roots of these disparities and calls for urgent, collective action to turn data into justice.
In this podcast, Dr. Valentin Fuster presents a comprehensive review of conduction disturbances following transcatheter aortic valve replacement (TAVR), highlighting key factors that contribute to the need for permanent pacemaker implantation. The discussion covers current management strategies, risks, and future perspectives, emphasizing the need for improved prediction methods and the evolving role of ambulatory monitoring and physiological pacing techniques.
In this podcast, Dr. Valentin Fuster reviews a pivotal study comparing the five-year outcomes of transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in low-risk patients with severe aortic stenosis. The study found that both treatments yielded similar mortality and stroke rates, reinforcing TAVR's non-inferiority to surgery, though long-term outcomes in younger patients and the impact of pacemaker implantation remain areas of concern.
In this podcast, Dr. Valentin Fuster discusses a pivotal study on the benefits of early ezetimibe initiation combined with statins after a myocardial infarction, showing improved cardiovascular outcomes. The study's findings suggest that early combination therapy reduces the risk of major cardiovascular events, urging healthcare pathways to adopt this approach as standard practice for better patient outcomes.
In this podcast, Dr. Valentin Fuster discusses a study on pre-pregnancy obesity and its long-term effects on pregnancy outcomes and cardiovascular health later in life. The research highlights how pre-pregnancy obesity and overweight increase the risk of gestational diabetes, hypertension, and future cardiovascular disease, underscoring the need for early weight management and more research on treatments like GLP-1 receptor agonists.
In this podcast, Dr. Valentin Fuster reviews the impact of catheter ablation on atrial fibrillation progression, summarizing a state-of-the-art article published in JACC. It explores how catheter ablation modifies the disease's mechanisms, reduces progression to persistent atrial fibrillation, and improves cardiovascular outcomes, suggesting that earlier intervention leads to better long-term results.
In this episode, Dr. Valentin Fuster reviews groundbreaking studies from the April 22, 2025 issue of JACC, covering key findings in valve replacement, pregnancy-related cardiovascular risk, and post-MI therapy. Plus, two cutting-edge reviews explore atrial fibrillation ablation and conduction disturbances after transcatheter valve procedures.
Hosts Mitsuaki Sawano, MD, and co-host Satoshi Shoji, MD, welcome Kenji Inoue, MD, to discuss the DROP-Asian ACS study—a multicenter trial evaluating the 0/1-hour algorithm for chest pain assessment across 12 hospitals in five Asian countries presented as a Late Breaking Clinical Trial at the ACC.25. Dr. Inoue shares key findings from this cluster-randomized trial of nearly 4,000 patients, highlighting the algorithm's practicality in Asia's diverse healthcare settings. Despite regional differenc...
In a rapidly changing world marked by societal divisions, technological advances in healthcare, and shifting views on expertise, the JACC Journals remain dedicated to advancing global cardiovascular health through a science-based and humanistic approach. Committed to evidence, integrity, and humanity, JACC focuses on rigorously evaluating research, guided by facts rather than ideology, and strives to address healthcare inequities while respecting patient autonomy. As a trusted platform, it empha...
In this podcast, Dr. Valentin Fuster discusses a groundbreaking study from JACC that explores how genetic risk and cardiovascular health in the first trimester of pregnancy predict hypertensive disorders, such as preeclampsia, gestational hypertension, and eclampsia. The research highlights the potential of improving cardiovascular health early in pregnancy as a preventive measure, especially for those at high genetic risk, and calls for more accessible, community-based interventions to better s...
In this episode, Dr. Valentin Fuster summarizes two pivotal studies from the April 15, 2025 issue of the JACC. The first paper discusses how adding cardiac troponins to traditional risk factors modestly improves cardiovascular risk prediction, while the second highlights how early cardiovascular health and genetic factors can predict hypertensive disorders in pregnancy, emphasizing the importance of early interventions and pre-pregnancy care to improve maternal health outcomes.
In this podcast, Dr. Valentin Fuster discusses a recent study on the use of cardiac troponins in predicting cardiovascular disease risk, showing a modest improvement when added to traditional risk factors. While the findings suggest potential benefits in population health, he emphasizes the importance of focusing on the eight core modifiable risk factors for cardiovascular disease rather than solely relying on biomarkers like cardiac troponins.
JACC Associate Editor Khurram Nasir, MBBS, FACC, speaks with author Michael J. Koren, MD, FACC, on his Featured Clinical Research study published in JACC and presented at ACC.25. This randomized, multicenter, double-blind, placebo-controlled, dose-ranging phase 2 study assessed efficacy, safety, and tolerability of AZD0780, a small molecule PCSK9 inhibitor. The study randomized 428 patients (426 started treatment) with hypercholesterolemia on standard-of-care statin therapy to daily oral adminis...
This interview with JACC: Associate Editor Neha J. Pagidipati, MD, FACC, and author Kausik Ray, MD, FACC, reviews Dr. Ray's phase one study on solbinsiran, an siRNA therapy targeting ANGPTL3 to reduce triglycerides and cardiovascular risk. Dr. Ray explains the study's findings, including significant reductions in triglycerides, ApoB, and LDL, with a favorable safety profile. The conversation also touches on the broader landscape of ANGPTL3 inhibitors, the implications of HDL reduction, and the a...
Join here for an insightful discussion with Federico Pappalardo, MD and Sanket Dhruva, MD, FACC on the groundbreaking ALT-SHOCK 2 RCT, the largest randomized trial on intra-aortic balloon pump therapy in heart failure cardiogenic shock. Learn about the trial's key findings, implications for clinical practice, and the future of mechanical circulatory support in this critically ill patient population.
Join JACC Associate Editor Khurram Nasir, MBBS, FACC, and author Rohan Khera, MD, FACC, as they discuss the latest study on tirzepatide presented at ACC.25 and published in JACC. Tirzepatide, a dual GIP/GLP-1 receptor agonist, exerts pleiotropic effects on cardiometabolic health. This study evaluated its efficacy in improving cardiometabolic outcomes in individuals with T2D. An individual participant data meta-analysis was conducted, pooling data from seven Phase 3 RCTs comparing tirzepatide wit...
This discussion between JACC: Clinical Electrophysiology Associate Editor Sumeet Chugh, MD, FACC and author Jonathan Drezner discuss this research study presented at ACC.25 and published in JACC. In the observational study, they identified cases of sudden cardiac arrest (SCA) among young competitive athletes >/=11 years old from 7/1/2014-7/30/2023. During the 9-year study period, overall survival after SCA (49%,range 30-66%) and survival after exertional SCA (57%,range 38-72%) increased. Blac...
Makoto Mori, MD, JACC: Associate Editor, is joined by author John K. Forrest, MD, FACC, discussing this study from Forrest et al presented at ACC.25 and published in JACC. Patients with severe aortic stenosis who were treated with either a supraannular self-expanding TAVR or surgery showed comparable rates of all-cause mortality and disabling stroke at 5 years, strengthening TAVR as a safe, effective, and durable alternative to surgery for patients, regardless of their surgical risk.
Hosts Mitsuaki Sawano, MD, and Regional Associate Editor Nobuhiro Ikemura, MD, welcome Takashi Ikenouchi, MD, a physician scientist at the Cedars-Sinai Medical Center, Smidt Heart Institute, to discuss the headline-grabbing "Gold Card" sale and a novel approach to atrial fibrillation: an embryological classification of arrhythmogenic triggers. While pulmonary vein isolation (PVI) remains the cornerstone of AF ablation, up to 30% of triggers originate outside the pulmonary veins, contributing to ...
